Topics (1-12) and Sub-Topics (a-z) |
|
Topics (1-12) |
Sub-Topics (a-z) |
|
1 |
Protein Misfolding & Aggregation |
1.a |
tau |
|
1.b |
Abeta |
|
1.c |
alpha-synuclein |
|
1.d |
TDP-43 |
|
1.e |
SOD-1 |
|
1.f |
FUS |
|
1.g |
parkin |
|
1.h |
PrP |
|
1.i |
dimers, trimers, oligomers |
|
1.j |
chaperones |
|
1.k |
clearance of misfolded proteins |
|
1.l |
other |
|
2 |
Cell, Molecular & Systems Biology |
2.a |
APP, APLPs, Abeta |
|
2.b |
tau |
|
2.c |
alpha-synuclein |
|
2.d |
TDP-43 |
|
2.e |
FUS |
|
2.f |
parkin |
|
2.g |
SOD-1 |
|
2.h |
PINK1 |
|
2.i |
DJ-1 |
|
2.j |
LRKK2 |
|
2.k |
PrP |
|
2.l |
alpha-secretase |
|
2.m |
beta-secretase |
|
2.n |
gamma-secretase, PS1, PS2, nicastrin, PEN-2, APH-1 |
|
2.o |
Abeta-degrading enzymes |
|
2.p |
ApoE |
|
2.q |
growth factors |
|
2.r |
GCPR, nicotinic, sigma-1 & other receptors |
|
2.s |
protein-protein interactions |
|
2.t |
network biology |
|
2.u |
metabolomics |
|
2.v |
transcriptomics |
|
2.w |
lipidomics |
|
2.x |
modeling of disease progression |
|
2.y |
other |
|
3 |
Pathophysiology & Disease Mechanisms |
3.a |
cell to cell transmission and spreading of pathology |
|
3.b |
prion-like mechanisms |
|
3.c |
synapse pathology |
|
3.d |
autophagy and lysosomes |
|
3.e |
proteasome and ubiquitin |
|
3.f |
oxidative damage |
|
3.g |
mitochondrial dysfunction |
|
3.h |
metabolism and insulin |
|
3.i |
inflammation |
|
3.j |
autoimmunity |
|
3.k |
lipids and lipoproteins |
|
3.l |
translational regulation |
|
3.m |
micro RNAs |
|
3.n |
kinases and phosphatases |
|
3.o |
cellular signalling |
|
3.p |
cell-cycle |
|
3.q |
blood-brain barrier |
|
3.r |
vasculature |
|
3.s |
neurogenesis and stem cells |
|
3.t |
glial cells |
|
3.u |
cell death |
|
3.v |
metal ions |
|
3.w |
calcium homeostasis |
|
3.x |
neural networks |
|
3.y |
aging |
|
3.z |
other |
|
4 |
Genetics |
4.a |
disease-causing mutations |
|
4.b |
genetic associations |
|
4.c |
genome-wide association studies (GWAS) |
|
4.d |
deep sequencing |
|
4.e |
epigenetics |
|
4.f |
non-coding RNA |
|
4.g |
other |
|
5 |
Risk Factors |
5.a |
aging |
|
5.b |
genetic |
|
5.c |
familial |
|
5.d |
metabolic |
|
5.e |
cardiovascular |
|
5.f |
environmental |
|
5.g |
infectious |
|
5.h |
autoimmune |
|
5.i |
neuroinflammation |
|
5.j |
co-moribidity |
|
5.k |
drug-induced and iatrogenic |
|
5.l |
other |
|
6 |
Epidemiology |
6.a |
population-based studies |
|
6.b |
patient cohort studies |
|
6.c |
gender differences |
|
6.d |
genetic epidemiology |
|
6.e |
other |
|
7 |
Therapeutic Targets & Mechanisms for Treatment |
7.a |
immunotherapy |
|
7.b |
Abeta |
|
7.c |
tau |
|
7.d |
alpha-synuclein |
|
7.e |
TDP-43 |
|
7.f |
SOD-1 |
|
7.g |
kinases |
|
7.h |
secretases & other proteases |
|
7.i |
other enzymes |
|
7.j |
neurotransmitter-based targets |
|
7.k |
nicotinic & other ionotropic receptors |
|
7.l |
sigma-1, metabotropic, muscarinic and other GPCRs |
|
7.m |
wnt signalling |
|
7.n |
anti-inflammatory targets |
|
7.o |
anti-oxidants |
|
7.p |
growth factors |
|
7.q |
cell transplantation |
|
7.r |
protein aggregation |
|
7.s |
misfolding and chaperones |
|
7.t |
gene therapy |
|
7.u |
RNAi-based therapy |
|
7.v |
synaptic plasticity and repair |
|
7.w |
adult neurogenesis |
|
7.x |
deep brain stimulation |
|
7.y |
neurosurgery |
|
7.z |
other |
|
8 |
Imaging |
8.a |
structural MRI |
|
8.b |
functional MRI |
|
8.c |
PET - amyloid |
|
8.d |
PET - alpha-synuclein |
|
8.e |
PET - tau |
|
8.f |
PET - glucose |
|
8.g |
PET - receptors |
|
8.h |
PET - oxygen |
|
8.i |
PET - other |
|
8.j |
CT |
|
8.k |
PET-CT |
|
8.l |
SPECT imaging |
|
8.m |
multimodal imaging |
|
8.n |
EEG & brain mapping |
|
8.o |
near infrared spectroscopy |
|
8.p |
MR spectroscopy |
|
8.q |
other |
|
9 |
Clinical Trials &
Clinical Studies |
9.a |
therapy |
|
9.b |
prevention |
|
9.c |
clinical trial design |
|
9.d |
neuroregeneration |
|
9.e |
disease-modifying |
|
9.f |
symptomatic |
|
9.g |
neuroprotection |
|
9.h |
biomarkers |
|
9.i |
diagnostics |
|
9.j |
companion diagnostics |
|
9.k |
transcranial magnetic stimulation |
|
9.l |
non-pharmacological interventions |
|
9.m |
cognitive training |
|
9.n |
deep brain stimulation |
|
9.o |
other |
|
10 |
Novel Animal Models |
10.a |
transgenic mice |
|
10.b |
transgenic rats |
|
10.c |
primate models |
|
10.d |
drosophila |
|
10.e |
zebra fish |
|
10.f |
pharmacological models |
|
10.g |
microtissues |
|
10.h |
lesion models |
|
10.i |
other |
|
11 |
e-Health, IT-based Care & alternative support |
11.a |
mobile applications |
|
11.b |
web-based care |
|
11.c |
physician networks |
|
11.d |
clinical trial sites |
|
11.e |
web-based training |
|
11.f |
caregiver support |
|
11.g |
social networks |
|
11.h |
art & music in therapy |
|
11.i |
life style support |
|
11.j |
functional foods |
|
11.k |
other |
|
12 |
Other |
12.a |
cell, molecular & systems biology |
|
12.b |
disease mechanisms |
|
12.c |
preclinical research |
|
12.d |
diagnostics |
|
12.e |
imaging |
|
12.f |
clinical trials |
|
12.g |
alternative hypotheses |
|
12.h |
other |